Compare NVAX & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVAX | MGNI |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 2.1B |
| IPO Year | 1995 | N/A |
| Metric | NVAX | MGNI |
|---|---|---|
| Price | $7.16 | $16.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $9.75 | ★ $26.80 |
| AVG Volume (30 Days) | ★ 3.2M | 2.2M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 219.02 |
| EPS | ★ 2.07 | 0.38 |
| Revenue | ★ $1,064,651,000.00 | $702,565,000.00 |
| Revenue This Year | $58.91 | $2.07 |
| Revenue Next Year | N/A | $10.93 |
| P/E Ratio | ★ $3.44 | $42.32 |
| Revenue Growth | ★ 20.27 | 6.27 |
| 52 Week Low | $5.01 | $8.22 |
| 52 Week High | $11.55 | $26.65 |
| Indicator | NVAX | MGNI |
|---|---|---|
| Relative Strength Index (RSI) | 58.83 | 51.94 |
| Support Level | $6.60 | $16.29 |
| Resistance Level | $7.00 | $16.66 |
| Average True Range (ATR) | 0.21 | 0.56 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 98.20 | 26.74 |
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Magnite is a supply-side advertising platform that provides technology and yield management solutions to content publishers, enabling them to monetize their digital advertising inventory. Magnite receives a percentage of all advertising inventory that it sells. 43% of Magnite's revenue is derived from connected television, or CTV, streaming platforms, 40% from mobile applications, and the remainder from general websites. Beyond the typical monetization responsibilities inherent to an SSP, Magnite also provides upstream advertising servers to CTV publishers, allowing them to have granular control over direct-sold, programmatic guaranteed, and open-auction logic. Magnite competes with other independent SSPs, supply path optimization solutions, and closed ecosystems like Meta.